349 related articles for article (PubMed ID: 30837603)
1. Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells.
Goulart MR; Hlavaty SI; Chang YM; Polton G; Stell A; Perry J; Wu Y; Sharma E; Broxholme J; Lee AC; Szladovits B; Turmaine M; Gribben J; Xia D; Garden OA
Sci Rep; 2019 Mar; 9(1):3574. PubMed ID: 30837603
[TBL] [Abstract][Full Text] [Related]
2. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
3. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
[TBL] [Abstract][Full Text] [Related]
4. Myeloid derived suppressor cells in peripheral blood can be a prognostic factor in canine transitional cell carcinoma.
Yokota S; Yonezawa T; Momoi Y; Maeda S
Vet Immunol Immunopathol; 2024 Mar; 269():110716. PubMed ID: 38308864
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomic profiling disclosed the role of DNA methylation and histone modifications in tumor-infiltrating myeloid-derived suppressor cell subsets in colorectal cancer.
Sasidharan Nair V; Saleh R; Toor SM; Taha RZ; Ahmed AA; Kurer MA; Murshed K; Alajez NM; Abu Nada M; Elkord E
Clin Epigenetics; 2020 Jan; 12(1):13. PubMed ID: 31941522
[TBL] [Abstract][Full Text] [Related]
6. CD205
Fu C; Fu Z; Jiang C; Xia C; Zhang Y; Gu X; Zheng K; Zhou D; Tang S; Lyu S; Ma S
Cancer Sci; 2021 Mar; 112(3):1011-1025. PubMed ID: 33368883
[TBL] [Abstract][Full Text] [Related]
7. Characterization of myeloid-derived suppressor cells and cytokines GM-CSF, IL-10 and MCP-1 in dogs with malignant melanoma receiving a GD3-based immunotherapy.
Hutchison S; Sahay B; de Mello SC; Sayour EJ; Lejeune A; Szivek A; Livaccari AM; Fox-Alvarez S; Salute M; Powers L; Milner RJ
Vet Immunol Immunopathol; 2019 Oct; 216():109912. PubMed ID: 31446208
[TBL] [Abstract][Full Text] [Related]
8. Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis.
Cole KE; Ly QP; Hollingsworth MA; Cox JL; Padussis JC; Foster JM; Vargas LM; Talmadge JE
Cell Immunol; 2021 May; 363():104317. PubMed ID: 33714729
[TBL] [Abstract][Full Text] [Related]
9. CD115
Zou Y; Kamada N; Seong SY; Seo SU
Commun Biol; 2023 Mar; 6(1):272. PubMed ID: 36922564
[TBL] [Abstract][Full Text] [Related]
10. Bacterial Killing Activity of Polymorphonuclear Myeloid-Derived Suppressor Cells Isolated From Tumor-Bearing Dogs.
Hlavaty SI; Chang YM; Orth RP; Goulian M; Planet PJ; Thamm DH; Punt JA; Garden OA
Front Immunol; 2019; 10():2371. PubMed ID: 31649676
[TBL] [Abstract][Full Text] [Related]
11. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling.
Sprouse ML; Welte T; Boral D; Liu HN; Yin W; Vishnoi M; Goswami-Sewell D; Li L; Pei G; Jia P; Glitza-Oliva IC; Marchetti D
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003475
[TBL] [Abstract][Full Text] [Related]
12. Temporal and spatial profile of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) in ischemic stroke in mice.
Kawano T; Shimamura M; Nakagami H; Kanki H; Sasaki T; Mochizuki H
PLoS One; 2019; 14(5):e0215482. PubMed ID: 31048856
[TBL] [Abstract][Full Text] [Related]
13. Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs.
Sherger M; Kisseberth W; London C; Olivo-Marston S; Papenfuss TL
BMC Vet Res; 2012 Oct; 8():209. PubMed ID: 23110794
[TBL] [Abstract][Full Text] [Related]
14. Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma.
Binsfeld M; Muller J; Lamour V; De Veirman K; De Raeve H; Bellahcène A; Van Valckenborgh E; Baron F; Beguin Y; Caers J; Heusschen R
Oncotarget; 2016 Jun; 7(25):37931-37943. PubMed ID: 27177328
[TBL] [Abstract][Full Text] [Related]
15. Polymorphonuclear MDSCs are enriched in the stroma and expanded in metastases of prostate cancer.
Wen J; Huang G; Liu S; Wan J; Wang X; Zhu Y; Kaliney W; Zhang C; Cheng L; Wen X; Lu X
J Pathol Clin Res; 2020 Jul; 6(3):171-177. PubMed ID: 32149481
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomic Analyses of Myeloid-Derived Suppressor Cell Subsets in the Circulation of Colorectal Cancer Patients.
Sasidharan Nair V; Saleh R; Toor SM; Alajez NM; Elkord E
Front Oncol; 2020; 10():1530. PubMed ID: 32984004
[TBL] [Abstract][Full Text] [Related]
17. CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients.
Karakasheva TA; Dominguez GA; Hashimoto A; Lin EW; Chiu C; Sasser K; Lee JW; Beatty GL; Gabrilovich DI; Rustgi AK
JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563330
[TBL] [Abstract][Full Text] [Related]
18. Protein Signature Differentiating Neutrophils and Myeloid-Derived Suppressor Cells Determined Using a Human Isogenic Cell Line Model and Protein Profiling.
Zhang Y; Hu J; Zhang X; Liang M; Wang X; Gan D; Li J; Lu X; Wan J; Feng S; Lu X
Cells; 2024 May; 13(10):. PubMed ID: 38786019
[TBL] [Abstract][Full Text] [Related]
19. Role of Myeloid-Derived Suppressor Cells in High-Dose-Irradiated TRAMP-C1 Tumors: A Therapeutic Target and an Index for Assessing Tumor Microenvironment.
Fu SY; Chen FH; Wang CC; Yu CF; Chiang CS; Hong JH
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1547-1558. PubMed ID: 33188861
[TBL] [Abstract][Full Text] [Related]
20. Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs.
Tannenbaum CS; Rayman PA; Pavicic PG; Kim JS; Wei W; Polefko A; Wallace W; Rini BI; Morris-Stiff G; Allende DS; Hamilton T; Finke JH; Diaz-Montero CM
Cancer Immunol Res; 2019 Oct; 7(10):1687-1699. PubMed ID: 31439615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
